ReviewHealth promotion perspectives2025
The association of serum phospholipids levels with chronic liver diseases: A systematic review of observational studies.
Review in Health promotion perspectives, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Trans fatty acids alter renal health in TGFβ3 mice with fibrosis revealed by metabolomics and lipidomics.iScience · 2026Article
- Can Variations in the Diet Quality Index Over Five Years Improve Renal Function and Lipid Profiles Among Patients with Type 2 Diabetes Mellitus? Results from the Prospective Azar Cohort Study.Advanced biomedical research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic liver disease (CLD) influences the levels of diverse metabolites that may be related to its pathogenesis. The study aimed to indicate the relation between CLD and the levels of phospholipids. Methods: In this systematic review, PRISMA guidelines were considered for reporting the results. Up to November 2024, the databases of MEDLINE (through PubMed), Scopus, Web of Science, and Google Scholar were searched. Case-control (CC) and cross-sectional (CS) studies explored the link between CLD and serum phospholipids. The Newcastle-Ottawa scale (NOS) for CC studies and the modified NOS scale for CS studies were applied to evaluate the quality of the included articles. Results: A total of 11304 articles were included. Eleven thousand duplicates were removed, 9304 studies were excluded, and 343 full-text articles were reviewed. Fifteen CC studies and four CS studies were included in this study. Quality assessment using NOS revealed most studies had low to moderate risk of bias, with scores ranging from 4 to 8 out of 9.The included studies verified a significant association between the levels of total PL (TPL), phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylserine (PS), phosphatidylinositol (PI), phosphatidic acid (PA), lysophosphatidylcholine (LPC), lysophosphatidylinositol (LPI) and lysophosphatidic acid (LPA) and liver diseases., with reported odds ratios ranging from 1.44 to 2.51 and correlation coefficients from -0.58 to 0.62. Conclusion: Phospholipid levels are associated with liver diseases. It is important to identify noninvasive ways to diagnose biological risk factors in patients with liver damage so they can be targeted for early treatment. Most of the included studies revealed significant alteration of phospholipid levels in CLD. Thus, the lipidome can predict liver dysfunction and prevent its attributed complications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.